French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which ...

(RTTNews) - Sanofi announced the acquisition of 2.3% of its shares from L'Oréal. This transaction is part of share buyback program announced on January 30, 2025. This will involve the acquisition ...

In a report released on January 30, David Evans from Kepler Capital maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price target of €92.00. The company’s shares closed ...

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their ... compared to 20.45% of a placebo group. For a high-dose group, those figures rose to 47.8% and 27.4 ...

Sanofi India Limited, (Previously known as Aventis Pharma Limited) was incorporated in May, 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Taylor Tepper covered banking, investing and pretty much everything else in personal finance for more than a decade, with his work appearing in the New York Times, Fortune and MONEY magazine, as ...

The senior guard, who is averaging 23.9 points, 3.8 rebounds, 1.8 assists and 1.8 steals per game, has the Yankees looking like the team to beat in City Section. Sierra Canyon boys’ basketball ...

Editor's Note: APYs listed in this article are up-to-date as of the time of publication. They may fluctuate (up or down) as the Fed rate changes. CNBC Select will update as changes are made public ...

Background Escitalopram is licensed for use at doses up to 20 mg but is used clinically at higher doses. There is limited published data at higher doses and none in the treatment of Major ...